Erasca, Inc. (ERAS) stock
Close on Nov 12, 2026Market cap $5.52BP/E –Yield 0.00%
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $5.52B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 6.02
- Dividend yield
- 0.00%
- Free cash flow yield
- -1.98%
Fundamentals
- Net income
- -$307.94M
- EPS, diluted
- -$0.99
- Free cash flow
- -$109.24M
- Book value per share
- $2.66
- Diluted shares
- 344M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $16.80
- Open
- $16.22
- Day's range
- $15.16 – $16.27
- Volume
- 4,897,368
- Average volume (20 days)
- 4,938,855
- Index membership
- Russell 2000 (since Sep 2021), Russell 3000 (since Nov 2021)
- Beta (5 years)
- 1.77
- 52-week range
- $2.34 – $24.28
- RSI (14 days)
- 54.6
- Volatility (1 year)
- 103.2%
- Relative volume
- 1.06×
- WACC
- 13.7%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ERAS | S&P 500 | Difference | ERAS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +2.1% | -2.7% | +4.8 pts | ||
| 3 months | -15.1% | -1.7% | −13.3 pts | ||
| Year to date | +324.2% | +11.9% | +312.3 pts | ||
| 1 year | +495.5% | +12.0% | +483.5 pts | ||
| 3 years | +685.1% | +78.2% | +606.9 pts | +98.7% | +21.2% |
| 5 years | -18.9% | +73.2% | −92.1 pts | -4.1% | +11.6% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Erasca filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- News
- Results
- Results
- News
About Erasca
Pharmaceutical Preparations
Erasca is a clinical-stage precision oncology company that discovers, develops, and commercializes targeted therapies for patients with cancers driven by the RAS/MAPK signaling pathway. The company’s modality-agnostic pipeline includes clinical-stage drug candidates such as ERAS-0015, a pan-RAS molecular glue, and ERAS-4001, a pan-KRAS inhibitor, as well as discovery-stage assets like ERAS-12, an anti-EGFR biparatopic antibody. Its therapies address multiple signaling nodes, direct RAS mechanisms, and pathway escape routes to overcome treatment resistance. Erasca designs its product candidates for individuals diagnosed with solid tumors and other malignancies associated with RAS and MAPK pathway alterations.
Company profile, executives and historyErasca stock: common questions
What is Erasca's stock price?
ERAS closed at $15.78 on Nov 12, 2026, down 6.07% on the day. Over the past 52 weeks it traded between $2.34 and $24.28.
What is Erasca's market cap?
Erasca was worth $5.52B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is ERAS's P/E ratio?
Erasca lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.99), so it has no meaningful P/E ratio.
Does Erasca pay a dividend?
No. Erasca has not paid a cash dividend over the last twelve months.
When does Erasca report earnings next?
Erasca's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has ERAS stock performed over the past year?
Including dividends, ERAS returned +495.5% over the past year, against +12.0% for the S&P 500.
How many ERAS shares are sold short?
37M shares were sold short at the latest FINRA report, 11.93% of the float, or 8.9 days of average trading volume.
Who are Erasca's competitors?
Companies most similar to Erasca by business, industry and size include VSTM, AVBP, KZIA, IMNM, CBIO.
See a number that looks wrong?